Sort by:
Need a comprehensive medical report on "Boehringer Ingelheim"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
Phase 2
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: BI 498306 50 mg QDDrug: BI 409306 10 mg QDDrug: BI 409306 100 mg QDDrug: BI 498306 25 mg QDDrug: Placebo
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 518
- Registration Number
- NCT02281773
- Locations
- 🇺🇸
Artemis Institute for Clinical Research, LLC, San Diego, California, United States
🇺🇸Uptown Research Institute, Chicago, Illinois, United States
🇺🇸Comprehensive Clinical Development, Inc., Cerritos, California, United States
Study to Compare the Effect of a Combination of Dipyridamole With Sustained Release and Acetyl Salicylic Acid (Aggrenox®) on the Performance Relevant to Safety and on the General Condition of Healthy Volunteers
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2014-10-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT02278302
Bioequivalence of Telmisartan as Telmisartan 80 mg/HCTZ 12.5 mg Fixed-dose Combination Tablet or as Two Telmisartan 40 mg Tablets in Healthy Male Volunteers
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 64
- Registration Number
- NCT02276391
Bioavailability of BI 10773 and Pioglitazone in Healthy Male Volunteers
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT02276365
Relative Bioavailability of Meloxicam 2 x 7.5 mg Tablets Compared to 15 mg Tablet and Dose Proportionality Over a Dose Range of 7.5 mg and 15 mg in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Treatment 1Drug: Treatment 2Drug: Treatment 3
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02276352
Influence of Food on the Bioavailability of Two Doses of Telmisartan/HCTZ Fixed-dose Combination in Japanese Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT02276378
BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 65
- Registration Number
- NCT02273388
- Locations
- 🇧🇪
1230.1.32002 Boehringer Ingelheim Investigational Site, Brussels, Belgium
🇧🇪1230.1.32001 Boehringer Ingelheim Investigational Site, Leuven, Belgium
Impact of Food on Pharmacokinetics and Pharmacodynamics of Asasantin ER in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Asasantin EROther: Standardized breakfast
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 28
- Registration Number
- NCT02273492
Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Asasantin ER (new formulation II - high)Drug: Asasantin ER (present commercial formulation)Drug: Asasantin ER (new formulation I - low)Drug: Asasantin ER (new formulation III - medium)
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19
- Registration Number
- NCT02273557
Study to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 54
- Registration Number
- NCT02273453